文献速递淋巴瘤造血干细胞移植与细胞治疗

未活化及IL-7培养的CD19特异性CAR T细胞富集干细胞表型且功能更优

Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior.
PubMed 文献 · Blood Adv · 2024-01-01

研究探讨用IL-7在无CD3刺激下生成CD19 CAR T细胞(NICE),发现该细胞富集T记忆干细胞、干性标志物表达保留、耗竭标志物表达更低且增殖潜力增强。在腹腔和皮下B细胞淋巴瘤体内模型中,NICE CD19 CAR T细胞显示出更优的治疗反应,提示可能改善B细胞恶性肿瘤结局并值得临床评价。

要点

  • IL-7可在无CD3刺激下完成慢病毒转导生成CD19 CAR T细胞(NICE)。
  • NICE CD19 CAR T细胞富集T记忆干细胞、耗竭标志物表达更低、增殖潜力增强。
  • 在腹腔和皮下B细胞淋巴瘤体内模型中,NICE细胞显示更优治疗反应。

核心结论

  • NICE CD19 CAR T细胞可能改善B细胞恶性肿瘤的结局,值得进行临床评价。

研究设计与样本

  • 研究使用IL-7在无CD3刺激条件下生成CD19 CAR T细胞,并与常规需CD3刺激的制备方案进行对比。
  • 在腹腔和皮下B细胞淋巴瘤体内模型中评估NICE CD19 CAR T细胞的治疗反应。

主要发现

  • NICE CD19 CAR T细胞富集T记忆干细胞群体,保留新的干性标志物,耗竭标志物表达更低,增殖潜力增加。
  • 研究结果与NICE CD19 CAR T细胞的植入一致,并在腹腔和皮下体内B细胞淋巴瘤模型中显示出更优的治疗反应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出这些结果提示NICE CD19 CAR T细胞可能改善B细胞恶性肿瘤结局,并值得临床评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-specific chimeric antigen receptor (CAR) T cells have demonstrated impressive responses in patients with relapsed and refractory B cell malignancies. However, many patients relapse or fail to respond to CD19 CAR T cells, demonstrating the need to improve its efficacy and durability. Current protocols for generating CAR T cells involve T cell activation through CD3 stimulation to facilitate efficient CAR transfer followed by ex vivo expansion with exogenous cytokines to obtain adequate cell numbers for treatment. Both T cell activation and expansion inevitably lead to terminal differentiation and replicative senescence, which are suboptimal for therapy. Interleukin-7 (IL-7) was previously shown to allow for lentiviral transduction of T cells in the absence of activation. In these studies, we used IL-7 to generate CD19 CAR T cells without stimulating CD3. Nonactivated and IL-7 cultured (NICE) CD19 CAR T cells were enriched with the T memory stem cell population, retained novel markers of stemness, had lower expression of exhaustion markers, and increased proliferative potential. Furthermore, our findings are consistent with engraftment of NICE CD19 CAR T cells and demonstrate a superior therapeutic response in both intraperitoneal and subcutaneous in vivo B cell lymphoma models. These results suggest that NICE CD19 CAR T cells may improve outcomes for B cell malignancies and warrant clinical evaluation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wang SY, Scurti GM, Dalheim AV, et al. Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior. Blood Adv. 2024. PMID: 37967375. doi:10.1182/bloodadvances.2023010607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。